LifeVantage Corporation

LFVN

US53222K2050

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:30:01 2024-04-26 pm EDT			5-day change	1st Jan Change
6.185 ^USD	-0.88%		-7.69%	+3.08%

Apr. 16	LifeVantage Corporation Enters Loan Agreement with Bank of America, N.A	CI
Mar. 20	Transcript : LifeVantage Corporation - Special Call

LifeVantage Corporation Provides Earnings Guidance for the Fiscal Year 2024

January 30, 2024 at 04:06 pm EST

LifeVantage Corporation provided earnings guidance for the fiscal year 2024. For the year, the company expects to generate revenue in the range of $207 million to $213 million, down from the previous range of $216 million to $226 million.

Latest news about LifeVantage Corporation

LifeVantage Corporation Enters Loan Agreement with Bank of America, N.A	Apr. 16	CI
Transcript : LifeVantage Corporation - Special Call	Mar. 20
LifeVantage Corporation Announces the Launch of its TrueScience Activated Skin Care Collection	Mar. 04	CI
Bradley Louis Radoff and Sudbury Capital Management Enter into Cooperation Agreement with LifeVantage Corporation	Feb. 15	CI
LifeVantage Corporation Appoints Dayton Judd to Its Board of Directors, Audit Committee and the Nominating and Corporate Governance Committee	Feb. 15	CI
LifeVantage Corporation Announces Expansion of LV360 into Canada, Mexico, and European Markets	Feb. 07	CI
Lifevantage Keeps Quarterly Cash Dividend at $0.035 a Share, Payable March 15 to Holders of Record March 1	Jan. 30	MT
Transcript : LifeVantage Corporation, Q2 2024 Earnings Call, Jan 30, 2024	Jan. 30
Earnings Flash (LFVN) LIFEVANTAGE CORPORATION Reports Q2 Revenue $51.6M, vs. Street Est of $54.6M	Jan. 30	MT
Earnings Flash (LFVN) LIFEVANTAGE CORPORATION Reports Q2 EPS $0.10	Jan. 30	MT
LifeVantage Corporation Provides Earnings Guidance for the Fiscal Year 2024	Jan. 30	CI
Tranche Update on LifeVantage Corporation's Equity Buyback Plan announced on November 27, 2017.	Jan. 30	CI
LifeVantage Corporation Declares Quarterly Dividend, Payable on March 15, 2024	Jan. 30	CI
LifeVantage Corporation Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Jan. 30	CI
Key Inflation Data Awaited as Exchange-Traded Funds, Equity Futures Rise Pre-Bell Thursday	Nov. 30	MT
Lifevantage Says Protandim Nrf2-TrueScience Combination Helps Cells 'Accurately' Respond To Stress Levels	Nov. 29	MT
LifeVantage Corporation Announces Executive Changes	Nov. 27	CI
Bradley Louis Radoff and Sudbury Capital Management?s Counsel Delivers a Letter to Counsel to LifeVantage Corporation	Nov. 14	CI
Declaration of Voting Results by LifeVantage Corporation	Nov. 13	CI
LifeVantage Corporation Provides Information to Shareholders	Nov. 09	CI
LifeVantage Corporation Approves Board Appointments	Nov. 09	CI
Earnings Flash (LFVN) LIFEVANTAGE CORPORATION Reports Q1 EPS $0.13	Nov. 09	MT
LifeVantage Corporation Provides Earnings Guidance for the Year 2024	Nov. 09	CI
Transcript : LifeVantage Corporation, Q1 2024 Earnings Call, Nov 09, 2023	Nov. 09
Earnings Flash (LFVN) LIFEVANTAGE CORPORATION Reports Q1 Revenue $51.4M	Nov. 09	MT

Chart LifeVantage Corporation

Duration

Period

More charts

Company Profile

LifeVantage Corporation is engaged in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. The Company's dietary supplements include its flagship Protandim family of products, LifeVantage Omega+, ProBio, IC Bright, and Daily Wellness dietary supplements. The Protandim product line includes Protandim NRF1 Synergizer, Protandim Nrf2 Synergizer, and Protandim NAD Synergizer. TrueScience is its line of skin, hair, bath and body, and targeted relief products. The Company also markets and sells Petandim, its companion pet supplement formulated to combat oxidative stress in dogs; Axio, its nootropic energy drink mixes, and PhysIQ, its smartweight management system, which includes PhysIQ Fat Burn and PhysIQ Prebiotic, all formulated to aid in weight management.

Sector

Pharmaceuticals

Calendar

2024-05-01 - Q3 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LIFEVANTAGE CORPORATION	+3.08%	79.59M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals